F5 and Rare hereditary thrombophilia: The RE-COVER/RE-COVER II and RE-MEDY studies did not report any issues regarding dabigatran etexilate treatment in the presence of thrombophilia; however, the authors did not distinguish between heterozygote and homozygote variants of factor V Leiden and factor II mutation [15].